Dissecting the Role of Estradiol in Mediating Gender-specific Anxiolytic and Prosocial Effects of Oxytocin

PHASE1CompletedINTERVENTIONAL
Enrollment

487

Participants

Timeline

Start Date

September 18, 2016

Primary Completion Date

January 25, 2020

Study Completion Date

January 25, 2020

Conditions
OxytocinEstrogenFear ExtinctionEmotion ProcessingMemory
Interventions
DRUG

Oxytocin nasal spray

Intranasal administration of 24 International Units, Oxytocin will be given 30 minutes before the fear extinction task (Study 1) or fMRI measurement (Study 2).

DRUG

Placebo nasal spray

The placebo spray contains the identical ingredients, except for the peptide itself. It will be given 30 minutes before the fear extinction task (Study 1) or fMRI measurement (Study 2).

DRUG

Estrogen Gel

Participants received a single dose of estradiol gel (Estramon 2 mg estradiol, Hexal AG, Holzkirchen, Germany), applied to their shoulder, 3 hours prior to the fear extinction task (Study 1) or fMRI measurement (Study 2).

DRUG

Placebo Gel

Participants received a single dose of the placebo gel (ultrasonic gel, 2 mg), applied to their shoulder, 3 hours prior to the fear extinction task (Study 1) or fMRI measurement (Study 2).

Trial Locations (1)

53105

Deparment of Psychiatry and Medical Psychology, Bonn

All Listed Sponsors
lead

University Hospital, Bonn

OTHER

NCT04330677 - Dissecting the Role of Estradiol in Mediating Gender-specific Anxiolytic and Prosocial Effects of Oxytocin | Biotech Hunter | Biotech Hunter